From roadmap to a sustainable end-to-end individualized therapy pathway

Area of Science:

• Biomedical Research
• Genetics
• Pharmacology

Background:

• Individualized (N-of-1) therapy development is emerging for serious genetic diseases.
• Existing roadmaps guide N-of-1 development, but gaps remain for broader implementation.
• Novel therapies are needed for patients with unique genetic variants lacking approved treatments.

Purpose of the Study:

• To reflect on addressing current gaps in N-of-1 therapy development.
• To propose an integrated and sustainable model for individualized interventions.
• To discuss requirements for scaling up N-of-1 therapy development and utilization.

Main Methods:

• Literature review and expert consensus on N-of-1 therapy development.
• Analysis of existing roadmaps and identification of implementation gaps.
• Discussion of critical components for large-scale N-of-1 therapy adoption.

Main Results:

• Key areas for advancement include sustainability, safety, efficacy, and regulatory pathways.
• Essential elements for scale-up involve registries, data sharing, tools, and long-term monitoring.
• Partnerships with patient advocates and innovative reimbursement models are crucial.

Conclusions:

• Recommendations focus on ethical considerations, education, tool development, data sharing incentives, and novel payment models.
• Advancing N-of-1 therapies requires a multi-faceted approach to ensure accessibility and sustainability.
• Shaping the future of individualized therapies necessitates collaboration and innovative strategies.